Progress toward development of a much-needed test for early detection of cancer of the urinary bladder and for monitoring patients after treatment is being reported in a recent article.
In the report, the University of Florida's Steve Goodison and colleagues at the University of Michigan note that urinary bladder cancer is among the five most common malignancies worldwide. Early detection and treatment dramatically increases patient survival rates. However, the existing urinalysis test has serious drawbacks. Consequently, the development of noninvasive urinalysis assays using reliable diagnostic markers would be of tremendous benefit to both patients and healthcare providers,the report points out.
Their research identified potential biomarkers for bladder cancer, including a protein present in the urine of patients with bladder cancer but not other individuals. It is the same protein linked to liver and ovarian cancer in previous studies. Although the protein appears promising as a biomarker, the researchers cite the need for further studies in large groups of bladder cancer patients to determine its usefulness.
Publication of this research is scheduled for the July 6 issue of ACS Journal of Proteome Research.
Article: Bladder Cancer Associated Glycoprotein Signatures Revealed by Urinary Proteomic Profiling
Cite This Page: